Shilpa Medicare Secures SEC Approval for World-First OERIS Long-Acting Injectable
Shilpa Medicare has received final approval from the CDSCO Subject Expert Committee for OERIS, a world-first extended-release ondansetron injection. The product, used for managing chemotherapy-induced nausea, offers five days of protection from a single dose and holds patent security until 2039.
Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility. Located in Dharwad, the plant enables end-to-end production of complex oncology biologics for global markets.
Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned an integrated Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This advanced unit enables the company to offer end-to-end development and production of complex oncology drug substances for the global pharmaceutical market.